ReviewTrends in biotechnology2017
Manufacturing Cell Therapies Using Engineered Biomaterials.
Review in Trends in biotechnology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Boolean Logic-Based Control Over Recombinant Protein Biomaterial Degradability and Therapeutic Delivery.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Shear-Induced CROSS (Cellular RedOx Spreading Shield) Assembly Sustains Neurotrophic Extracellular Vesicle Production for Functional Neural Networks.Advanced functional materials · 2026Article
- Bioprinted Constructs in the Regulatory Landscape: Current State and Future Perspectives.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- A Review on the Stability Challenges of Advanced Biologic Therapeutics.Pharmaceutics · 2025Review
- Biomaterials for Cell Manufacturing.ACS macro letters · 2024Article
- Advanced Technologies for Potency Assay Measurement.Advances in experimental medicine and biology · 2023Article
- Biomaterials-mediated CRISPR/Cas9 delivery: recent challenges and opportunities in gene therapy.Frontiers in chemistry · 2023Review
- Synthetic Thermo-Responsive Terpolymers as Tunable Scaffolds for Cell Culture Applications.Polymers · 2022Article
- Biomaterials to enhance stem cell transplantation.Cell stem cell · 2022Review
- Every road leads to Rome: therapeutic effect and mechanism of the extracellular vesicles of human embryonic stem cell-derived immune and matrix regulatory cells administered to mouse models of pulmonary fibrosis through different routes.Stem cell research & therapy · 2022Article
- Navigating ethical challenges in the development and translation of biomaterials research.Frontiers in bioengineering and biotechnology · 2022Article
- Integrating Biomaterials and Genome Editing Approaches to Advance Biomedical Science.Annual review of biomedical engineering · 2021Article
- Reduced angiovasculogenic and increased inflammatory profiles of cord blood cells in severe but not mild preeclampsia.Scientific reports · 2021Article
- Advanced Materials to Enhance Central Nervous System Tissue Modeling and Cell Therapy.Advanced functional materials · 2020Article
- Review
- Properties of immature and mature dendritic cells: phenotype, morphology, phagocytosis, and migration.RSC advances · 2019Article
- Trinity of Three-Dimensional (3D) Scaffold, Vibration, and 3D Printing on Cell Culture Application: A Systematic Review and Indicating Future Direction.Bioengineering (Basel, Switzerland) · 2018Review
- Bottom-up approaches in synthetic biology and biomaterials for tissue engineering applications.Journal of industrial microbiology & biotechnology · 2018Article
- The Role of Biomaterials as Angiogenic Modulators of Spinal Cord Injury: Mimetics of the Spinal Cord, Cell and Angiogenic Factor Delivery Agents.Frontiers in pharmacology · 2018Review
- Noninvasive measurement of cell/colony motion using image analysis methods to evaluate the proliferative capacity of oral keratinocytes as a tool for quality control in regenerative medicine.Journal of tissue engineeringArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Emerging manufacturing processes to generate regenerative advanced therapies can involve extensive genomic and/or epigenomic manipulation of autologous or allogeneic cells. These cell engineering processes need to be carefully controlled and standardized to maximize safety and efficacy in clinical trials. Engineered biomaterials with smart and tunable properties offer an intriguing tool to provide or deliver cues to retain stemness, direct differentiation, promote reprogramming, manipulate the genome, or select functional phenotypes. This review discusses the use of engineered biomaterials to control human cell manufacturing. Future work exploiting engineered biomaterials has the potential to generate manufacturing processes that produce standardized cells with well-defined critical quality attributes appropriate for clinical testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.